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Editorial on the Research Topic
Biomarkers in Drug Hypersensitivity
This special issue on biomarkers in drug hypersensitivity consists of 11 articles focusing
on recent advancements related to this exciting field. Biomarkers, especially those based on
pharmacogenomics testing, have proved to be extremely useful for type A adverse drug reactions
(ADRs). Clinical practice guidelines based on biomarker testing are presently being developed
and updated for type A ADRs (see, for instance the Clinical Pharmacogenetics Implementation
Consortium website https://cpicpgx.org/guidelines/).
The World Health Organization defines ADRs as any noxious, unintended, and undesired
effect of a drug that occurs at doses used for prevention, diagnosis, or treatment. Major
ADR categories include type A—predictable reactions (about 80% of all ADRs), and type B—
unpredictable, reactions. Where predictable reactions are usually dose dependent, related to the
known pharmacologic actions of the drug, and occur in otherwise healthy subjects, unpredictable
reactions are generally dose independent, unrelated to the pharmacologic actions of the drugs, and
occur only in susceptible subjects. Compared to type A, type B ADRs are extremely complex and
these include drug intolerance, drug idiosyncrasy, drug allergy, and pseudo-allergic reactions.
Böhm and Cascorbi elegantly summarized the different reaction types, mechanisms and known
biomarkers for type B ADRs. Among these, the HLA-B alleles are highly relevant for delayed T-
cell mediated reactions with abacavir (Martin et al., 2014) and carbamazepine (Leckband et al.,
2013). In another article included in this Research Topic Sukasem et al. confirmed the relevance of
HLA-B in the occurrence of adverse reactions (e.g., Stevens-Johnson syndrome and toxic epidermal
necrolysis) secondary to the use of allopurinol in Thai patients. A previously published CPIC
guideline contraindicated the use of allopurinol for carriers of HLA-B∗5801 (Hershfield et al.,
2013), although it should be borne in mind that the Thai population displays an unusually high
frequency for carriers of such variant alleles and therefore, it is crucial to measure the strength of
the association in this population in order to gain more ground on the clinical implementation
of preemptive pharmacogenomics tests for HLA-B alleles. In spite of the utility of HLA testing,
clinical implementation is hampered due to its technical complexity and because of the potential
source of heterogeneity related to the use of diverse genotyping procedures (revised in Martin
et al., 2012). The contribution by Chua and Ng in this Research Topic analyzes the potential of an
additional procedure for HLA testing based on nanopore sequencing mechanisms, seeking a rapid
and useful tool for the detection of genetic markers for drug hypersensitivity. They concluded that
the procedure is promising, although there is still room for improvement.
Besides genetic biomarkers, clinical and analytical biomarkers provide crucial information. A
careful assessment of clinical phenotypes, for instance, is essential to improve the accuracy of
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biomarkers as predictors of disease evolution and/or therapy
response. Pérez-Alzate et al. identified an unusual clinical
presentation among patients who were selective responders to
paracetamol or a single NSAID, which usually present with
urticaria and/or angioedema and anaphylaxis: A subgroup of
selective responders presented with rhinitis and/or asthma with
no skin manifestation. These findings suggest the occurrence of
a new clinical phenotype for selective responders to NSAIDs. A
particularly severe phenotype of drug-induced hypersensitivity is
drug-induced liver injury. Robles-Díaz et al. summarized current
knowledge on biomarkers related to diagnosis, phenotypes,
clinical course and prognosis. Among these, mechanistic-based
biomarkers such as the proteins High-mobility group box 1 and
Keratin-18, or the micro-RNA miR-122 hold great promise.
Drug-induced hypersensitivity is often related to metabolic
activation and haptenization of drug metabolites. Hence,
factors that influence the pharmacokinetics of drug and
metabolites may contribute to the development of some
drug-induced hypersensitivity reactions. This implies that
processes such as biotransformation and excretion, which
are typically involved in type A adverse drug reactions,
may have a role in hypersensitivity reactions too. Nuin
et al. demonstrated that the active trifusal metabolite
2-hydroxy-4-trifluoromethylbenzoic acid, which causes
photoallergy, is covalently bound to a protein model after
photoactivation.
Other clinical presentations of drug-induced hypersensitivity
reactions correspond to non-allergic mechanisms, usually
associated with the release of inflammatory transmitters. Of
these, eicosanoids play a prominent role in inflammation and
are thought to be involved in cross hypersensitivity to NSAIDs.
In this regard, it has been shown that some genetic variants of
the arachidonic acid pathway influence the risk of developing
such cross-hypersensitivity reactions (Cornejo-Garcia et al.,
2012). Cornejo-García et al. analyzed the genetic variability
of prostaglandin and leukotriene receptors, seeking for genetic
biomarkers which alone, or combined with polymorphisms of
the genes coding for the cyclooxygenase enzymes (Agundez et al.,
2014, 2015), may help in the understanding of the mechanisms
underlying cross-hypersensitivity to NSAIDs.
Several signal transduction pathways participate and
modulate the development and the clinical presentation of drug
hypersensitivity once the reaction is triggered. One of these
depends on the interplay of IgE response and the consequent
release of mediators. Amo et al. studied the genetic variability
of the high-affinity IgE receptor (Fcε RI) and the variability in
genes coding for enzymes involved in histamine homeostasis
in patients with selective hypersensitivity to NSAIDs. They
concluded that polymorphisms in the diamine oxidase (DAO)
gene that have functional consequences (Ayuso et al., 2007)
are involved in the clinical presentation of these selective
hypersensitivity reactions, as has been reported previously in
patients with cross hypersensitivity to NSAIDs (Agundez et al.,
2012). Sánchez-Gómez et al. reviewed the role of enzymes
involved in the generation of danger or co-stimulatory signals,
such as GSTP1-1 and aldose reductase, in drug hypersensitivity.
These enzymes are important regulators of the balance of
inflammatory mediators, they participate in allergic processes,
they can metabolize drugs and they are covalently modified
by drugs, thus indicating a high potential for these enzymes in
future research onmechanisms underlying drug hypersensitivity.
Two papers in this research topic focused on in vitro
models. Galbiati et al. analyzed the potential of the use of
THP-1 cell lines and interleukin-8 production together with
CD86 and CD54 expression for pre-clinical immune safety
evaluation studies. The proposed in vitro method benefits
from a rationalistic approach with the idea that allergenic
drugs share with chemical allergens common mechanisms of
cell activation. In addition, they described the experimental
conditions and markers to identify drug sensitizers, also
assessing the state of the art of in vitro models to assess the
allergenic potential of drugs. Steiner et al. reviewed the literature
on a different model used in clinical studies, the Basophil
Activation Test (BAT). After analyzing the potential of this
procedure in hypersensitivity to beta-lactams, quinolones, neuro-
muscular blocking agents, contrast media, chemotherapeutics,
and NSAIDs, among other drugs, they concluded that BAT
constitutes a safe, complement of in vivo tests in immediate drug
hypersensitivity reactions.
We would like to thank all the contributors whose valuable
work has helped us to present wide-ranged aspects in this field.
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